Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Altheos has announced the dosing of first patient in a Phase 2a clinical trial of its lead investigational candidate, ATS907.
Subscribe to our email newsletter
ATS907 is a Rho kinase (ROCK)-selective inhibitor in development as a next-generation eye drop for the reduction of elevated intraocular pressure (IOP) in primary open angle glaucoma and ocular hypertension.
The randomized controlled investigator masked dose-ranging safety and efficacy first-in-human study enrolled subjects with primary open angle glaucoma and/or ocular hypertension.
The trial employs a two-stage adaptive design to examine a number of different doses of ATS907 ophthalmic formulation and to provide preliminary information on safety, tolerability and efficacy following 28 days of administration.
Altheos chief medical officer Barbara Wirostko said the drug showed excellent ocular surface penetration, and is rapidly converted into a more active form in the anterior chamber after topical dosing.
The company has raised an additional $12.5m in its Series A financing from the existing and additional investors to advance the drug candidate through Phase 2 clinical and Phase 3 trials.
Altheos anticipates to commence the second stage of this trial, a comparison of ATS907 and latanoprost (a prostaglandin analogue).